Anti-spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents.
SARS-CoV-2
nursing homes
vaccination
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
12
04
2022
received:
16
02
2022
accepted:
23
04
2022
pubmed:
30
4
2022
medline:
23
9
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
Duration of post-vaccination protection against COVID-19 in nursing home (NH) residents is a critical issue. The objective of this study was to estimate the duration of the IgG(S) response to the mRNA BNT162b2 vaccine in NH residents with (COV-Yes) or without (COV-No) history of SARS-CoV-2 infection. A 574 COV-Yes and COV-No NH residents were included in 2 cohorts: Main (n = 115, median age 87 years) or Confirmatory (n = 459, median age 89 years). IgG(S) quantification was carried out at three different time points following the BNT162b2 vaccine: three (1st) and seven (2nd) months after the 2nd dose, and 1 month after the 3rd dose (3rd quantification) in the Main cohort, and twice (2nd and 3rd) in the Confirmatory cohort. The seroneutralization capacity according to COVID-19 history was also measured in a subgroup of patients. Neutralization capacity was strongly correlated with IgG(S) levels (R In old subjects living in NH, history of SARS-CoV-2 infection provides a clear advantage in the magnitude and duration of high IgG(S) titers following the 2nd dose. Importantly, the 3rd dose induces a much more pronounced IgG(S) response than the 2nd dose in COV-No subjects, the effect of which should be able to ensure a prolonged protection against severe forms of COVID-19 in these subjects.
Sections du résumé
BACKGROUND
Duration of post-vaccination protection against COVID-19 in nursing home (NH) residents is a critical issue. The objective of this study was to estimate the duration of the IgG(S) response to the mRNA BNT162b2 vaccine in NH residents with (COV-Yes) or without (COV-No) history of SARS-CoV-2 infection.
METHODS
A 574 COV-Yes and COV-No NH residents were included in 2 cohorts: Main (n = 115, median age 87 years) or Confirmatory (n = 459, median age 89 years). IgG(S) quantification was carried out at three different time points following the BNT162b2 vaccine: three (1st) and seven (2nd) months after the 2nd dose, and 1 month after the 3rd dose (3rd quantification) in the Main cohort, and twice (2nd and 3rd) in the Confirmatory cohort. The seroneutralization capacity according to COVID-19 history was also measured in a subgroup of patients.
RESULTS
Neutralization capacity was strongly correlated with IgG(S) levels (R
CONCLUSIONS AND RELEVANCE
In old subjects living in NH, history of SARS-CoV-2 infection provides a clear advantage in the magnitude and duration of high IgG(S) titers following the 2nd dose. Importantly, the 3rd dose induces a much more pronounced IgG(S) response than the 2nd dose in COV-No subjects, the effect of which should be able to ensure a prolonged protection against severe forms of COVID-19 in these subjects.
Identifiants
pubmed: 35484977
doi: 10.1111/jgs.17837
pmc: PMC9115082
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
RNA, Messenger
0
Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2552-2560Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-15-IDEX-04-LUE
Informations de copyright
© 2022 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.
Références
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
J Clin Virol. 2022 Jan;146:105052
pubmed: 34920374
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263
pubmed: 35176007
J Clin Epidemiol. 2004 Mar;57(3):229-36
pubmed: 15066682
JAMA. 2021 Dec 28;326(24):2524-2526
pubmed: 34724529
Clin Chem Lab Med. 2021 Mar 15;59(8):1463-1467
pubmed: 33711225
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Clin Chem Lab Med. 2021 Sep 08;59(12):2010-2018
pubmed: 34492749
Front Med (Lausanne). 2022 Feb 15;9:822316
pubmed: 35242786
N Engl J Med. 2022 Apr 7;386(14):1375-1377
pubmed: 35139265
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Science. 2021 Mar 25;:
pubmed: 33766944
J Am Geriatr Soc. 2021 Jun;69(6):1441-1447
pubmed: 33768521
Vaccine. 2022 Jan 24;40(3):531-535
pubmed: 34893341
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Stat Med. 1983 Apr-Jun;2(2):243-51
pubmed: 6359318
J Am Geriatr Soc. 2022 Sep;70(9):2552-2560
pubmed: 35484977
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):632-638
pubmed: 33914721